Xencor (NASDAQ:XNCR) Rating Reiterated by Wedbush

Wedbush reaffirmed their outperform rating on shares of Xencor (NASDAQ:XNCR – Free Report) in a report released on Thursday, RTT News reports. The firm currently has a $34.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $36.00. Several other equities analysts have also commented on XNCR. Piper Sandler restated […]

Leave a Reply

Your email address will not be published.

Previous post Acacia Research Co. (NASDAQ:ACTG) Short Interest Down 33.9% in May
Next post Needham & Company LLC Reaffirms “Buy” Rating for Vertex (NASDAQ:VERX)